/

PVCT

Provectus Biopharmaceuticals, IClosed

0.0550+0.00 +1.85%USD

OTC Markets OTCQB · as of Oct 13, 16:00 ET · 15m delay

Open

0.0491

Prev close

0.0540

Day range

0.04830.0491

52-week range

0.03800.0780

Volume

5540.00×

Mkt cap

23.12M

P/E ttm

—

Fwd P/E

—

EPS ttm

-0.0100

Div yield

0.00%

Earnings

—

From 52w high

−29.49%

Price Chart

Yahoo Finance · delayed

PVCTOct 14, 2026O 0.0470H 0.0530L 0.0470C 0.0500−0.0050 (−9.09%)Vol 114.50K

SMA 500.0561
SMA 2000.0576

1Y change −35.90% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PVCT Provectus Biopharmaceuticals, I · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.66%
1 month: −10.71%
3 months: −21.88%
6 months: −5.66%
Year to date: −10.71%
1 year: −34.21%

Valuation & ownership

Market cap: 23.12M
Enterprise value: 23.37M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -5.63
EPS (ttm): -0.0100
EPS (forward): —
Beta (5y monthly): 0.90
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 420.28M
Float: 389.41M
Short % of float: 0.78%
Short ratio (days): 0.49
Held by insiders: 7.48%
Held by institutions: 0.03%
Avg volume (3m): 130.94K
50-day average: 0.0561
200-day average: 0.0576
52-week change: −34.21%
S&P 500 52-week: +15.71%

Technicals (daily)

RSI (14): 39.1
vs 50-day SMA: −10.94%
vs 200-day SMA: −13.21%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.68%
Realised vol (20d, ann.): 61.9%
From 52-week high: −35.90%
From 52-week low: +31.58%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 0
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Provectus Biopharmaceuticals, I

Yahoo Finance profile

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Sector: Healthcare
Industry: Biotechnology
Employees: 6
Headquarters: Knoxville, TN, United States
Website: provectusbio.com
Officers

SEAS

Seasonality · PVCT

2007–2026 · monthly returns

Strongest month Feb +18.63%Weakest month Jun −8.67%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-8.9	-7.8	8.5	11.8	14.0	6.2	-8.7	-9.5	0.0	-3.5			−1.8%
2025	-11.7	0.0	-5.7	-7.0	-14.0	-6.2	17.3	-9.1	11.3	-19.1	-12.5	-11.1	−53.3%
2024	29.2	20.2	22.8	8.2	-14.1	-25.9	-18.3	-12.6	8.9	6.1	13.5	1.7	+25.0%
2023	18.5	25.8	2.5	-18.8	1.5	-16.9	-3.5	-6.4	-16.7	-5.9	87.5	-36.0	−11.1%
2022	18.2	6.2	-2.9	-9.0	-1.6	-6.7	3.6	-6.9	-9.3	2.0	86.0	16.1	+96.4%
2021	31.0	-7.9	-2.9	-4.4	13.8	-6.8	1.4	-12.9	6.6	-13.8	-3.6	1.9	−5.2%
2020	-4.8	-1.7	-10.2	-17.0	2.3	-2.2	63.6	12.5	7.4	-19.5	-12.9	-4.9	−7.9%
2019	16.0	-1.7	-1.8	-21.4	13.6	26.0	7.9	2.9	-5.7	3.0	0.0	-7.4	+26.0%
2018	-20.7	16.9	-15.8	25.0	-7.5	-4.1	-1.4	0.0	0.0	-1.4	0.0	-27.5	−39.0%
2017	-15.0	135.3	7.5	18.6	-13.7	-29.5	-6.5	-3.4	0.0	28.6	5.6	115.8	+310.0%
2016	-1.3	22.1	-19.1	28.9	-24.5	0.0	-21.6	-57.6	-19.5	-46.5	-67.9	17.6	−94.9%
2015	5.0	9.6	-11.5	9.0	-11.8	-31.0	-6.5	-17.8	38.6	-16.5	-4.2	-15.2	−51.3%
2014	-47.3	43.3	35.7	-3.2	-68.6	14.7	3.4	11.4	3.0	-4.8	-8.3	-10.1	−66.8%
2013	5.4	33.9	-7.6	-6.8	-2.9	-1.5	-0.8	17.8	1.3	0.0	11.0	181.9	+330.4%
2012	9.9	-3.4	1.2	-3.4	3.6	-3.4	-10.7	1.2	-11.7	-3.7	-10.1	-3.4	−30.9%
2011	-14.9	16.9	16.6	-7.3	9.9	-8.1	-3.9	-5.1	0.0	-6.5	-10.3	3.8	−13.8%
2010	-7.7	52.4	16.4	-8.7	6.6	-24.1	-8.2	-5.0	-3.1	36.6	-25.2	-1.1	+3.3%
2009	3.3	-1.1	1.1	28.4	-3.7	-12.3	7.8	-19.8	6.7	-8.4	12.6	-7.1	−1.1%
2008	-24.4	-11.5	9.6	-0.8	-8.0	-21.7	10.0	30.3	23.3	-34.0	-9.5	-3.2	−46.5%
2007	-2.1	-1.3	28.7	7.4	5.7	-4.8	5.0	25.0	19.0	-15.6	4.3	-21.8	+44.5%

INSD

Insider Activity · PVCT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 17, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 62.00 per share.	132.2K	$8.19M
Jun 4, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 0.87 per share.	94.4K	$82.35K
May 21, 2026	Pershing Edward V CpaChief Executive Officer	—	320.9K	—
May 14, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 200.56 per share.	226.5K	$45.43M
Apr 28, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 43.62 per share.	302K	$13.17M
Apr 1, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 1.98 per share.	34K	$67.27K
Feb 19, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 16.28 per share.	471.8K	$7.68M
Jan 29, 2026	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 32.84 per share.	377.4K	$12.40M
Jun 25, 2025	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 67.19 per share.	122.7K	$8.24M
Apr 28, 2025	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 66.12 per share.	188.8K	$12.48M
Feb 26, 2025	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 2.54 per share.	679.5K	$1.73M
Jan 29, 2025	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 77.88 per share.	512.9K	$39.94M
Nov 28, 2024	Pershing Edward V CpaChief Executive Officer	Conversion of Exercise of derivative security at price 59.98 per share.	188.8K	$11.32M

PVCT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PVCT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Provectus Biopharmaceuticals, I

Seasonality · PVCT

Insider Activity · PVCT

Congress Trades · PVCT

Investors Holding PVCT

Investors Holding PVCT

Congress Trades · PVCT

Insider Activity · PVCT

Seasonality · PVCT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Provectus Biopharmaceuticals, I

Earnings & Dividends

News